Comparative Pharmacology
Head-to-head clinical analysis: HYDERGINE LC versus METHYLERGONOVINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDERGINE LC versus METHYLERGONOVINE MALEATE.
HYDERGINE LC vs METHYLERGONOVINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoloid mesylates (dihydroergotoxine) act as a partial agonist/antagonist at dopamine (D1, D2), serotonin (5-HT1, 5-HT2), and alpha-adrenergic receptors. They enhance cerebral metabolism and increase blood flow via vasodilation and neuroprotection.
Ergot alkaloid; partial agonist/antagonist at alpha-adrenergic, serotonin (5-HT2), and dopamine receptors; directly stimulates uterine smooth muscle contractions.
Oral, 1 mg three times daily. Titrate up to 2 mg three times daily if needed.
0.2 mg intramuscularly or intravenously once, may repeat as needed every 2-4 hours for a maximum of 5 doses.
None Documented
None Documented
Terminal elimination half-life: 12–15 hours. Clinical context: steady-state achieved in 2–3 days; allows once-daily dosing.
Biphasic: initial (alpha) ~10-30 min; terminal (beta) ~2-3 hours in normal subjects; prolonged to ~6-12 hours in hepatic impairment or pregnancy
Renal (80% as metabolites, <1% unchanged); biliary/fecal (20%).
Renal (approximately 60-80% as metabolites, <1% unchanged); biliary/fecal (minor route, approximately 20-30%)
Category C
Category D/X
Ergot Alkaloid
Ergot Alkaloid